Johnson & Johnson agreed to pay an initial $2.2 billion for biotech firm Ollin Biosciences. It also struck a deal with investment firm Blackstone to fund development of Ollin’s lead eye-care product candidate.
Eli Lilly agreed to pay up to $1.5 billion to acquire Calytrix Bio, a closely held biotechnology company backed by JPMorgan. Calytrix is developing treatments for a group of rare blood cancers.




Comments (0)
No comments yet. Be the first!